Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? by Curran, HV et al.
Psychological Medicine
cambridge.org/psm
Original Article
Cite this article: Curran HV, Hindocha C,
Morgan CJA, Shaban N, Das RK, Freeman TP
(2018). Which biological and self-report
measures of cannabis use predict cannabis
dependency and acute psychotic-like effects?
Psychological Medicine 1–7. https://doi.org/
10.1017/S003329171800226X
Received: 15 June 2018
Revised: 27 July 2018
Accepted: 2 August 2018
Key words:
Biological markers; cannabinoids; cannabis;
predictors of dependence; predictors of
psychotic-like; self-report measures
Author for correspondence:
H. Valerie Curran, E-mail: v.curran@ucl.ac.uk
© Cambridge University Press 2018. This is an
Open Access article, distributed under the
terms of the Creative Commons Attribution
licence (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted re-use,
distribution, and reproduction in any medium,
provided the original work is properly cited.
Which biological and self-report measures of
cannabis use predict cannabis dependency and
acute psychotic-like effects?
H. Valerie Curran1, Chandni Hindocha1, Celia J. A. Morgan1,2, Natacha Shaban1,
Ravi K. Das1 and Tom P. Freeman1,3
1Clinical Psychopharmacology Unit, University College London, Gower St, London, UK; 2Department of
Psychology, University of Exeter, Washington Singer Building, Perry Road, Exeter, UK and 3National Addiction
Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK
Abstract
Background. Changes in cannabis regulation globally make it increasingly important to deter-
mine what predicts an individual’s risk of experiencing adverse drug effects. Relevant studies
have used diverse self-report measures of cannabis use, and few include multiple biological
measures. Here we aimed to determine which biological and self-report measures of cannabis
use predict cannabis dependency and acute psychotic-like symptoms.
Method. In a naturalistic study, 410 young cannabis users were assessed once when intoxi-
cated with their own cannabis and once when drug-free in counterbalanced order.
Biological measures of cannabinoids [(Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD),
cannabinol (CBN) and their metabolites)] were derived from three samples: each participant’s
own cannabis (THC, CBD), a sample of their hair (THC, THC-OH, THC-COOH, CBN,
CBD) and their urine (THC-COOH/creatinine). Comprehensive self-report measures were
also obtained. Self-reported and clinician-rated assessments were taken for cannabis depend-
ency [Severity of Dependence Scale (SDS), DSM-IV-TR] and acute psychotic-like symptoms
[Psychotomimetic State Inventory (PSI) and Brief Psychiatric Rating Scale (BPRS)].
Results. Cannabis dependency was positively associated with days per month of cannabis use
on both measures, and with urinary THC-COOH/creatinine for the SDS. Acute psychotic-like
symptoms were positively associated with age of first cannabis use and negatively with urinary
THC-COOH/creatinine; no predictors emerged for BPRS.
Conclusions. Levels of THC exposure are positively associated with both cannabis depend-
ency and tolerance to the acute psychotic-like effects of cannabis. Combining urinary and
self-report assessments (use frequency; age first used) enhances the measurement of cannabis
use and its association with adverse outcomes.
Introduction
Changes in the regulation of cannabis for recreational as well as medical use are currently
continuing apace in many parts of the world. How patterns of use will subsequently change
is not known, but even a small percentage increase in the current 183 million users worldwide
will mean a considerable surge in absolute numbers. Quantifying the relative adverse and
beneficial effects of cannabis and its constituent cannabinoids is, therefore, an important
research priority (Curran et al., 2016). Cannabis use is associated with a 2-fold increased
risk of developing a psychotic disorder (Marconi et al., 2016). Less attention has been paid
to the much more common problem of cannabis addiction. It is estimated that 31% of past
year cannabis users in the USA meet DSM-IV criteria for abuse or dependence (Hasin
et al., 2015). However, the majority will be resilient and use cannabis without incurring serious
mental health harms.
What predicts an individual’s vulnerability or resilience to experiencing the harmful effects
of cannabis? Several factors are currently thought to be important including early adolescent
initiation of use (Coffey et al., 2003; Mokrysz et al., 2016), genetic factors (Di Forti et al., 2012;
Morgan et al., 2016), concurrent tobacco use (Hindocha et al., 2015) and frequent (especially
daily) cannabis use (Coffey et al., 2003; Chen et al., 2005). Other factors that may be important
include the level of Δ9-tetrahydrocannabinol (THC) and other cannabinoids – especially can-
nabidiol (CBD) – in the strains that individuals use (Morgan and Curran, 2008; Morgan et al.,
2010; Di Forti et al., 2015; Curran et al., 2016; Freeman et al., 2018).
One impediment to drawing conclusions about these risk factors is the varying measures of
cannabis use that different studies employ. Despite growing international interest in this issue,
there are currently no agreed standardised measures for assessing cannabis use in research
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(Yücel et al., 2016; Hindocha et al., 2017; Kögel et al., 2017).
Although the majority of studies employ self-report measures
(e.g. frequency of use; years used) few include questions on
potency, dose and strain of cannabis (van der Pol et al., 2014).
A minority employ biological measures, and when these are
used there is much diversity in both the types of samples taken
(e.g. hair, saliva, plasma, urine, actual cannabis used) and analyses
subsequently carried out. Most estimate levels of
Δ9−tetrahydrocannabinol (THC) and/or its metabolites, some-
times also cannabidiol (CBD) and less often other cannabinoids
(Morgan and Curran, 2008; Demirakca et al., 2011; Freeman
et al., 2014; Yücel et al., 2016).
If we could predict which variations in measures of cannabis
use are and are not associated with adverse effects, then this
would inform harm-reduction strategies which in turn would
benefit those using cannabis for either recreational or medicinal
purposes. Further, there are pragmatic reasons to explore which
measures may be more or less associated with adverse outcomes
because biological measures can be seen as personally intrusive
and samples can be expensive to analyse.
We, therefore, set out to explore associations between multiple
measures of cannabis use and two types of outcomes: the main
harm we focussed on was dependence on cannabis; we also inves-
tigated acute psychotic-like effects that individuals experienced
after ingesting the drug. Each of these outcomes was assessed
by both self-report and by clinician-ratings. Three types of bio-
logical measures were used: analyses of cannabinoids (THC,
CBD) and related metabolites in (i) participants’ hair, (ii) their
urine and (iii) samples of cannabis each had used acutely.
Self-report measures of use were: age of onset, years used, amount,
frequency, time to smoke 3.5 g, the amount spent per week on
buying cannabis, time since last use and preference or not for
high potency cannabis strains. Our aim was to determine which
measure or combination of measures best predicted the two
outcomes.
We hypothesised firstly that using cannabis more frequently
and using high (as opposed to low) potency varieties would
be associated with increased rates of cannabis dependency
(Morgan et al., 2010; Freeman and Winstock, 2015; Freeman
et al., 2018). Secondly, we hypothesised that the use of high
potency strains would lead to more acute psychotic-like experi-
ences than the use of low potency strains (Di Forti et al., 2015).
Thirdly, we hypothesised that CBD might mitigate the harmful
effects of THC on both cannabis dependence and acute psychosis-
like symptoms (Morgan and Curran, 2008; Bhattacharyya et al.,
2010; Morgan et al., 2010; Englund et al., 2013).
Method
Design & participants
A repeated measures design was used whereby participants were
tested on two separate days 7 ± 2 days apart in their own
homes, once when acutely intoxicated with their own cannabis
and once when non-intoxicated (Morgan et al., 2016). Session
order was counterbalanced so that approximately 50% of partici-
pants were intoxicated on the first test day, non-intoxicated on the
second, and 50% vice versa.
Inclusion criteria were: aged 16–24 years, fluent English, using
cannabis at least once a month for at least a year, no learning
impairments, no clinical diagnosis of a substance use disorder
and no history of, or current, psychotic illness. We aimed to
recruit 200 daily users of cannabis and 200 ‘recreational’ users
(using less than daily). Regular users (>once/month) of any
drug except cannabis, tobacco or alcohol were excluded.
Participants were recruited via advertisement and word of
mouth. In all 410 completed the study, of whom 194 reported
daily use and 216 less frequent use. This study was approved by
UCL’s Research Ethics Committee.
Procedure
Participants gave written, informed consent on both testing days
and were paid at the end of the second day. They were texted 24 h
before each testing day to remind them to abstain from using
alcohol or other drugs from then until after testing had finished.
On the intoxicated test day (before testing), participants gave a
urine sample. Prior to testing they also provided a 0.3 g sample
of the cannabis they were about to smoke and testing began
immediately after the participant had finished smoking it. On
the non-intoxicated day, a hair sample was taken from each par-
ticipant of which 3 cm (from the scalp) was analysed. Researchers
were fully trained to administer and score clinician-rated as well
as other measures.
Assessments
Outcome variables
Cannabis dependence: The Severity of Dependence Scale (SDS) was
used to provide a self-report measure of psychological aspects of
cannabis dependence (Gossop et al., 1995; Piontek et al., 2008).
SDS is scored out of 15 and a cut-off of 3+ has been used for
indexing cannabis dependence (Swift et al., 1998; Martin et al.,
2006). Clinical diagnosis of cannabis dependence was based on
DSM-IV-TR criteria (American Psychiatric Association, 2000): a
maladaptive pattern of cannabis use leading to clinically signifi-
cant impairment or distress, manifested by at least three of the
six criteria within the last 12 months.
Psychotic-like symptoms: self-rated symptoms were assessed
with the Psychotomimetic States Inventory (PSI; Mason et al.,
2008) which was completed on both test days. An abridged
version of the Brief Psychiatric Rating Scale (BPRS) (Krystal
et al., 1994; Ventura et al., 2000) was used as the clinician-rated
measure of psychotic-like symptoms. On both scales, a change
score was calculated (score on intoxicated minus score on the
non-intoxicated day) and used as the measures of acute
psychotic-like symptoms.
Predictor variables
Biological variables
Cannabinoids in cannabis samples: The 0.3 g sample of the can-
nabis that each participant provided was analysed for concentra-
tions (% of sample weight) of THC (THC and THC acid) and of
CBD (CBD and CBD acid) by gas chromatography coupled to
mass spectrometry (Forensic Science Service, Birmingham).
Urine: urine collected on the intoxicated day was analysed for
THC-COOH concentrations (limit of quantification: 2 ng/ml).
These were corrected for creatinine concentrations (mg/ml) and
are expressed as THC-COOH/creatinine (ng/mg); Alere, UK.
Hair: the hair sample was a 3 cm segment cut from the scalp of
each participant on the non-intoxicated day. Gas chromatography
coupled to mass spectrometry was used to determine CBD, THC,
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CBN, THC:COOH, and THC:OH (Alere, UK). Consistent with
previous studies (Morgan and Curran, 2008; Yücel et al., 2016)
and with research indicating lack of valid quantification of canna-
bis use by hair (Taylor et al., 2017) samples were classified accord-
ing to whether each analyte was present or absent.
Self-report variables
Drug history: a comprehensive cannabis use history was taken
including age cannabis use first started, years used, days per
month used, the time taken to smoke 1/8th ounce (3.5 g), time
since last use and money spent on cannabis per week. Participants
additionally completed a modified Cannabis Experience
Questionnaire (Barkus et al., 2006). This included questions about
participants’ preference (yes/no) for high potency cannabis
(skunk, sensimilla) as opposed to other strains (e.g. resin/hash,
low potency herbal).
Demographic variables: Age and Sex data were recorded at
screening.
Statistical analyses
Analyses were conducted in Stata/IC v. 15.1 (StataCorp, College
Station, TX) and SPSS v.23 (IBM Corp, Armonk, NY).
DSM-IV-TR diagnosis of cannabis dependence was coded as 0
or 1 (dependent, not dependent; not dependent was the reference
group). SDS was non-normally distributed with a negative skew
that could not be corrected by transformation, therefore it was
coded as a dichotomous variable (dependent, not dependent
coded 0 or 1) based on an adult cut-off of 3 (not dependent
was the reference group). Hair cannabinoid/cannabinoid metabo-
lites were coded as present or absent (0 or 1; absent was the ref-
erence group). Sex was coded as female or male (1 or 2; male was
the reference group). Finally, preference for high potency canna-
bis was coded as present or absent (preference for other strains or
no preference; coded as 0 or 1 with absent as the reference
category). We correlated demographic covariates, biological and
self-reported predictors with the four outcome variables. We
used Pearson’s product moment correlations (r) or Spearman’s
rho (rs) for correlations between continuous variables, point
biserial correlation (rpb) for correlations between dichotomous
and continuous variables and the Phi coefficient (rw) for the asso-
ciation between two dichotomous variables (this was chosen over
chi-square as it accounts for the number of participants and is a
measure of effect size). Predictors were included in the model-
fitting process if they were significant correlates at a conservative
α threshold of ⩽0.001. For each outcome variable, we entered all
correlated variables into forward-fit linear models (binary logistic
models for SDS and DSM-IV-TR) starting with the null model.
We chose mixed effects modelling approach using maximum
likelihood estimation in order to fit both fixed and random effects
as appropriate, and for improved handling of missing data com-
pared with generalised linear model approaches. Candidate vari-
ables selected from the correlational analysis ( p⩽ 0.001) were
added as fixed effects. Variables were retained in the model if
they significantly improved model fit as assessed by a lower
Bayesian Information Criteria (BIC) and a significant (α⩽ 0.05)
Likelihood Ratio Test. We chose to use the BIC over other good-
ness-of-fit statistics as it penalises model complexity, protecting
against overfitting. Variable entry order was determined with uni-
variate BIC values with lower BIC values representing better
model fit (online Supplementary Table 2). The final mixed effects
models were checked for violation of assumptions.
Multicollinearity was not a concern in any model (all VIFs⩽
1.76). A correlation matrix between self-report and biological pre-
dictor variables can be found in Supplementary Table 3. In all
final models, a random intercept for ‘participant’ was added to
investigate if it improved model fit. The unstructured variance-
covariance structure was selected. Random effects parameters did
not improve model fit and were non-significant in all models, did
not change the pattern of results, and therefore were not included
in any of the final models.
Results
Sample characteristics
In all, 410 individuals completed the study, they were aged
M (S.D.) 20.56 (1.68) years and 27% (113) were female.
Participants’ mean age of first cannabis use was 14.94 (2.05)
years, they had been using cannabis on average for 4.88 (2.36)
years and used it 16.87 (10.95) days per month. They had last
used cannabis 4.20 (7.24) days previously. Participants took
10.31 (17.25) days to smoke 3.5 g (one-eighth of an ounce) of can-
nabis and spent £20.26 (£22.64) per week on the drug. Full
descriptive statistics are in Supplementary Table 1 which specifies
the number of participants for whom data on each variable was
available. Some hair samples were not heavy enough for analysis
leaving 344 which were fully analysed; for cannabis donated prior
to ingestion full analyses were successfully conducted on 366
samples (see online Supplementary Table 1 for full details).
Outcome variables
Cannabis dependence: 43.7% of participants met the cut-off for
cannabis dependence on the SDS and 48.4% met DSM-IV-TR
criteria for cannabis dependence.
Psychotic-like symptoms: Cannabis robustly increased
psychotic-like symptoms according to both self-report assessment
on the PSI (t383 = 10.067, p < 0.001, d = 0.516) and clinical assess-
ment on the BPRS (t401 = 7.857, p < 0.001, d = 0.413). The mean
Fig. 1. Cannabis increased psychotic-like symptoms as
measured by (a) self-report on the PSI, Psychotomimetic
States Inventory; (b) clinical assessment on the BPRS,
Brief Psychiatric Rating Scale. Error bars are 95%
confidence intervals.
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increase in psychotic-like symptoms was 8.61 (16.83) for the PSI
and 3.91 (9.97) for the BPRS (Fig. 1).
Biological and self-report measures of cannabis use:
associations with outcome variables
Cannabis dependence: self-reported (SDS)
Cannabis dependence (SDS) was positively correlated with
THC-COOH/creatinine in urine (rpb(345) = 0.350, p⩽ 0.001),
THC in hair (rw(412) = 0.206, p⩽ 0.001), CBD in hair (rw(412)
= 0.178, p⩽ 0.001), CBN in hair (rw(412) = 0.215, p⩽ 0.001)
THC-COOH in hair (rw(412) = 0.170, p⩽ 0.001), THC-OH in
hair (rw(412) = 0.135, p = 0.006), days per month of cannabis
use (rpb(398) = 0.486, p⩽ 0.001), preference for high potency can-
nabis (rw(412) = 0.212, p⩽ 0.001) and the amount of money spent
on cannabis per week (rpb(411) = 0.412, p⩽ 0.001). Cannabis
dependence (SDS) was negatively correlated with last use of
cannabis (rpb(401) =−0.244, p⩽ 0.001) and time to smoke 3.5 g
(rpb(392) =−0.199, p⩽ 0.001). Univariate BIC values ranked in
order (from lowest to highest) are shown in Supplementary
Table 2. In the final model cannabis dependence indexed by the
SDS was positively associated with both THC-COOH/creatinine
in urine and days per month of cannabis use (Table 1).
Cannabis dependence: clinician-rated (DSM-IV-TR)
Cannabis dependence (DSM–IV-TR) was associated with greater
THC-COOH/creatinine in urine (rpb(344) = 0.228, p < 0.001),
more days per month of cannabis use (rpb(397) = 0.431, p⩽ 0.001),
time to smoke 3.5 g (rpb(391) =−0.208, p⩽ 0.001), a preference for
high potency cannabis strains (rw(411) = 0.165, p = 0.001) and
more amount of money spent on cannabis per week (rpb(410) =
0.345, p⩽ 0.001). Univariate BIC values ranked in order (from
lowest to highest) are shown in Supplementary Table 2. In the
final model, DSM-IV-TR diagnosis of cannabis dependence was
positively associated with days per month of cannabis use (Table 2).
Acute psychotic-like symptoms: self-reported (PSI)
Self-reported psychotic-like symptoms (PSI) correlated positively
with both THC-COOH/creatinine in urine (r(324) = −0.196,
p < 0.001) and age of first cannabis use (r(384) = 0.206,
p < 0.001). Univariate BIC values ranked in order (from lowest
to highest) are shown in Supplementary Table 2. In the final
model (Table 3) cannabis-induced psychotic-like symptoms
were positively associated with age of first cannabis use, and
negatively associated with THC-COOH/creatinine in urine.
Table 1. Associations between biological and self-report measures of cannabinoid exposure and cannabis dependence on the SDS
OR S.E.
95% CI
z pLower Upper
THC-COOH/creatinine 1.004 0.001 1.0010 1.0060 3.0110 0.0026
Days per month of cannabis use 1.104 0.017 1.0710 1.1390 6.3050 0.0000
Days to smoke 3.5 g of cannabis 1.000 0.011 0.9800 1.0210 0.0010 0.9991
Constant 0.105 0.037 0.0530 0.2090 −6.4430 0.0000
Bold significant associations at p < 0.05.
Table 2. Associations between biological and self-report measures of cannabinoid exposure and cannabis dependence (DSM-IV-TR)
DSM-IV-TR (n = 331) OR S.E.
95% CI
z pLower Upper
THC-COOH/creatinine 1.000 0.001 0.999 1.002 0.441 0.659
Days per month of cannabis use 1.068 0.016 1.036 1.101 4.260 0.000
Money spent on cannabis per week 1.016 0.010 0.997 1.035 1.650 0.099
Constant 0.207 0.050 0.130 0.332 −6.555 0.000
Bold significant associations at p < 0.05.
Table 3. Associations between biological and self-report measures of cannabinoid exposure and cannabis-induced psychotic-like symptoms on the PSI
B S.E.
95% CI
z pLower Upper
Age of first cannabis use 1.588 0.433 0.738 2.437 3.664 0.0002
THC-COOH/creatinine −0.011 0.003 −0.017 −0.004 −3.131 0.0017
Constant −13.801 6.587 −26.711 −0.891 −2.095 0.0361
Bold significant associations at p < 0.05.
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Acute psychotic-like symptoms: clinician-rated (BPRS)
Clinician-rated psychotic-like symptoms (BPRS) correlated negatively
with age (r(400) =−0.127, p = 0.011), THC in hair (rpb(402) =
−0.135, p = 0.007), CBD in hair (rpb(402) =−0.123, p = 0.013) and
positively with CBN in hair (rpb(402) = 0.116, p = 0.020). None of
these variables met the criteria for inclusion in the final model
(α⩽ 0.001).
Discussion
The findings of this study provide converging evidence that a
combination of biological and self-report measures provides the
best model fit for predicting both dependence and acute
psychotic-like effects of cannabis in healthy young cannabis users.
Cannabis dependence was most strongly predicted by the
number of days per month that the individual used the drug,
with the greater frequency associated with greater dependency.
This was the case for both self-ratings (SDS) and clinician-ratings
(DSM-IV-TR) and was hypothesised based on the findings of
many previous studies (Curran et al., 2016). In addition, on the
self-rating measure, level of THC-COOH/creatinine in urine
improved model fit, with higher urinary levels predicting
increased dependency. In terms of specific cannabinoids, the
importance of the level of the THC metabolite in predicting
dependence supports the hypothesis that higher levels of THC
ingested are associated with increased risk of dependency
(Curran et al., 2016; Freeman et al., 2018). The average THC con-
tent of cannabis samples was approximately 10% and ranged
widely. In contrast, average CBD content was less than 1% with
a much narrower range of values. This reflects the current canna-
bis market in many countries with a predominance of high
potency ‘skunk’. Indeed, Potter et al. (2018)’s recent analysis of
UK police seizures found that 94% of strains were completely
lacking in CBD. CBD was detected in the hair of a third of our
participants but was not predictive/protective of dependence or
psychotic-like symptoms. These findings suggest a clear role
for higher THC levels predicting dependency whilst the near
absence of CBD suggests we cannot evaluate the role it plays
from our data.
In terms of acute psychotic-like effects, again a combination of
biological (urine) and self-report (age of first use) measures pro-
vided the optimal model fit on the self-rated measure (PSI).
Quantitative measurements of THC-COOH/creatinine in urine
samples taken before using cannabis on the intoxicated day were
again a strong predictor. However, the association was negative,
such that lower levels in urine when sober predicted a greater
increase in psychotic-like symptoms when acutely intoxicated
with cannabis. This strongly suggests a tolerance effect whereby
lower levels of THC-COOH/creatinine would reflect less (at least)
recent use of cannabis and a resulting stronger effect of the drug.
Indeed, there were very strong correlations between THC-COOH/
creatinine and days since last use of cannabis (r =−0.57; 32% shared
variance) and days used per month (r = 0.68; 46% shared variance).
This supports our previous findings that a greater increased in
psychotic-like symptoms (again measured with the PSI) was asso-
ciated with the less frequent use of cannabis (Mason et al., 2008;
Morgan et al., 2012). D’Souza et al. (2008) found similar
tolerance effects to the psychotomimetic effects of THC in frequent
cannabis users and similar tolerance has been reported for the acute
cognitive-impairing effects of cannabis (Ramaekers et al., 2009).
It is likely that the same tolerance mechanism explains why the
age of first use was positively associated with a greater increase in
psychotic-like symptoms (PSI) from the sober to the acutely
intoxicated state. Being older at first use of cannabis predicted
higher levels of acute psychotic-like symptoms, suggesting
that those individuals who started using at a younger age had
developed greater tolerance to these acute effects of the drug.
No significant predictors emerged for clinician ratings of
psychotic-like effects (BPRS). This measure was sensitive to the
acute effects of cannabis showing a very significant increase in
scores when participants were intoxicated. The increase in
psychotic-like effects on the BPRS also correlated positively
with those in the PSI. At the same time the variance of scores
on the BPRS was much less than on the PSI which may have miti-
gated against the sensitivity of the BPRS as an outcome. Further,
the self-rating measure was specifically developed to be sensitive
to the psychotomimetic effects of drugs like cannabis and keta-
mine so its greater sensitivity than a brief clinician screening
tool is unsurprising.
Which self-report and biological variables are most important
for inclusion in future studies?
The two key variables of urinary THC-COOH/creatinine and self-
reported frequency of use were stronger predictors than other
measures of cannabis use. On the basis of our findings, these
two measures are most important for measuring cannabis use
and its consequences, and should be prioritised in future research
studies such as observational studies investigating cannabis
harms, as well as randomised controlled trials aiming to reduce
levels of cannabis use. It is important to note that in addition
to the urinary data, objective measures of cannabinoids and
their metabolites in other biological samples (users’ own canna-
bis, samples of hair) were modestly associated with self-report
measures of cannabis use, as well as measures of harm in explora-
tory correlations. Although these measures did not emerge as
strong predictors of either dependence or acute psychotic-like
effects, they may be useful adjunctive measures or to test specific
hypotheses [e.g. CBD in hair as a measure of long-term protection
from harm (Morgan and Curran, 2008; Demirakca et al., 2011;
Yücel et al., 2016)]. Here we did not find a protective effect of
CBD measured in hair which may well reflect the near negligible
levels of CBD in UK cannabis (Potter et al., 2018). Further, we did
not have a measure for CBD metabolites in urine which could
have provided a more accurate measure of dose of CBD
consumed.
Strengths of this study include a sample of over 400 young
cannabis users and high levels of dependency (over 43%) in the
sample, which reflected our deliberate recruiting of daily as well
as recreational users. Further, we obtained very significant acute
psychotic-like effects of cannabis on the intoxicated day. This
we used as an index of clinically relevant changes, as a study of
psychotic disorder would require much larger sample sizes
including clinically diagnosed populations. Our findings that
early onset of cannabis use predicted less transitory acute
psychotic-like effects contrasts with epidemiological findings of
early-onset increasing the risk of developing a psychotic disorder
(Di Forti et al., 2014) although they are consistent with evidence
from experimental studies (D’Souza et al., 2008). A limitation
endemic to naturalistic studies was that we had limited informa-
tion of the dose of THC that participants ingested. A further
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limitation was that biological analyses were available for 89% of
cannabis, 85% of urine and 84% of hair samples rather than the
full 100% (410 participants). Finally, due to the cross-sectional
design of this study, we are unable to establish the existence or
direction of causality. Other potential measures of cannabis
which may be useful to employ include objectively quantifying
cannabis in preparations such as ‘joints’ rolled (Hindocha et al.,
2017; Kögel et al., 2017; Hindocha et al., 2018).
In summary, key measures of cannabis use which are positively
predictive of increased drug dependence are frequency (days per
month used) and a quantitative measure of urinary THC:
COOH/creatinine. The same urinary THC:COOH/creatinine
measure also negatively predicted acute psychotic-like effects,
alongside self-reported age of first cannabis use. Most biological
variables, although positively correlated with outcome measures,
were not strong predictors of outcomes. In this context, costly
analyses of hair and cannabis samples appear less important in
predicting dependence or transitory psychotic-like effects. These
findings could usefully inform future studies needing relevant
measures of cannabis use, for example, the longitudinal ABCD
study (Lisdahl et al., 2018), which currently includes measure-
ment of cannabinoids in hair but does not include a quantitative
index of THC:COOH/creatinine in urine.
As cannabis now stands poised to join alcohol and tobacco as a
legal drug in many parts of the world, the prediction of who is
resilient or vulnerable to its harms is increasing in importance.
In terms of cannabis dependence, our findings suggest the opti-
mal harm reduction strategy is to reduce the frequency of using
the drug. In terms of measures, this study strongly implies that
future studies generally include a self-report measure of days
per month used and urinary THC-COOH/creatinine levels.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S003329171800226X
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